Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegloticase - Horizon Therapeutics plc

Drug Profile

Pegloticase - Horizon Therapeutics plc

Alternative Names: KRYSTEXXA; Methoxypolyethylene glycol uricase; PEG urate oxidase; PEG-uricase; PEGylated uricase; Polyethylene glycol-uricase; Puricase; Urate-oxidase-PEG

Latest Information Update: 24 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University; Mountain View Pharmaceuticals
  • Developer Horizon Pharma Rheumatology; Savient Pharmaceuticals
  • Class Antigouts; Oxidoreductases; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Urate oxidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gout
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout

Most Recent Events

  • 20 Jun 2019 Horizon Therapeutics initiates enrolment in the phase IV MIRROR trial in Gout (Treatment-experienced, Combination therapy) in USA (IV) (NCT03994731)
  • 08 May 2019 Horizon Therapeutics plans a registrational MIRROR trial for Gout in June 2019
  • 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top